A phase II multicenter study comparing the efficacy of the oral angiogenesis inhibitor nintedanib with the intravenous cytotoxic compound ifosfamide for treatment of patients with advanced metastatic soft tissue sarcoma after failure of systemic non-oxazaphosporine-based first line chemotherapy for inoperable disease "ANITA"
|Trial Status||All trial activities ended|
Date of activation: 07-Jul-2017
Date Step1 close: 22-Nov-2019
|Data management at EORTC||Yes|
Randomized open label
|Targeted Sample size||EORTC Groups: 158 - All Groups: 158|
|Type of cancer|